Table 4. Effectiveness of the perindopril shown for the subgroup of the study cohort with newly diagnosed hypertension. * significant difference from previous visit, p < 0.001 .
| Baseline (n=424) |
Visit 1 (3 months from the baseline) (n=421) |
Visit 2 (6 months from the baseline) (n=412) |
Visit 3 (9 months from the baseline) (n=408) |
Δbaseline-Visit 3 | |
|---|---|---|---|---|---|
| Systolic blood pressure (mmHg) | 157.4±12.5* | 141.0±11.8* | 134.6±10.8* | 131.0±8.7* | 26.6±12.4* |
| Diastolic blood pressure (mmHg) | 95.5±7.8* | 86.5±7.6* | 82.3±7.3* | 80.1±8.0* | 15.5±9.7* |
| Percent of patients achieving systolic normotension (<140 mmHg) | 0% | 158 (37.5%) | 266 (64.6%) | 328 (80.4%) | 80.4% |
| Percent of patients achieving diastolic normotension (<90 mmHg) | 0% | 225 (53.4%) | 330 (80.1%) | 372 (91.2%) | 91.2% |
| Percent of patients achieving both systolic and diastolic normotension (<140/90 mmHg) | 0% | 113 (26.8%) | 234 (56.8%) | 310 (7.,0%) | 76.0% |
| Percent of patients with reduction of systolic pressure ≥10 mmHg | 0% | 332 (78.9%) | 383 (92.9%) | 397 (97.3%) | 97.3% |
| Percent of patients with reduction of diastolic pressure ≥5 mmHg | 0% | 346 (82.2%) | 386 (93.7%) | 394 (96.6%) | 96.6% |